Surefire Medical said it brought in $18.2 million in a Series B funding round it plans to use to further development of its infusion device for liver cancer.
The Westminster, Colo.-based medical device company said new backer Super Angel investors joined existing investors MCG Partners, Partisan Management Group and High Country Ventures in the round.
Surefire said it plans to use the funds “to expand product development, clinical trials, operations and marketing,” according to a press release. The company is working on a minimally invasive direct-to-target infusion device for liver cancer patients.
“Thanks to the enthusiastic support of our funders, we can expand our worldwide sales, particularly into the Asia-Pacific market, where we recently received regulatory clearance. The funding also enables Surefire to fuel company growth with the development of our next-generation infusion system, which will reach into the smallest vessels and further advance minimally-invasive cancer treatment,” CEO Jim Chomas said in prepared remarks.
A year ago Surefire won 510(k) clearance from the FDA for its suite of angiographic catheters. In June 2012 the federal watchdog agency granted 510(k) clearance for the company’s high-flow microcatheter.